ERS3945890
SRA accession
B-cell
http://purl.obolibrary.org/obo/CL_0000236
cell type
B-CLL Sample11 - Human B-chronic lymphocytic leukemia - Sample11
description
Italy
geographic location (country and/or sea)
Homo Sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
Homo Sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
scientific name
Male
http://purl.obolibrary.org/obo/PATO_0000384
sex
In B-chronic lymphocytic leukemia (B-CLL) the interaction between leukemic cells and the environmental niches confers drug resistance and promotes tumor cells survival. The Bruton’s tyrosine kinase inhibitor ibrutinib is one of the first-in-class molecules available for the treatment of B-CLL patients able to disrupt the microenvironment protection. However, the emerging mechanisms of resistance affecting patients’ survival call for new therapeutic strategies. The purpose of the current study was to investigate the ability of ibrutinib plus the MDM2-inhibitor nutlin-3 to counteract the tumor microenvironment protective effect
submission description
GSB-1351
submission identifier
Dual BTK and MDM2 inhibition effects in microenvironment protected chronic lymphocytic leukemia cells
submission title
Blood
http://purl.obolibrary.org/obo/UBERON_0000178
tissue type